Carregant...
The next step toward GMP-grade production of engineered immune cells
Removing less potent T cell subsets as well as poorly- or non-engineered cells can optimize effectiveness of engineered T cell therapy against cancer. We have recently described a novel, GMP-ready method for the purification of engineered immune cells that might further boost the clinical success of...
Guardat en:
| Publicat a: | Oncoimmunology |
|---|---|
| Autors principals: | , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Taylor & Francis
2015
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4801490/ https://ncbi.nlm.nih.gov/pubmed/27057450 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2015.1076608 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|